Current status of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer

References

• Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol.19(3), 666–675 (2001).
   PubMed Web of Science ®Google Scholar
• Sanderson KM, Stein JP, Skinner DG. The evolving role of pelvic lymphadenectomy in the treatment of bladder cancer. Urol. Oncol.22(3), 205–211 (2004).
   Google Scholar
• Frank I, Cheville JC, Blute ML et al. Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy: clinicopathologic features associated with outcome. Cancer97(10), 2425–2431 (2003).
   PubMed Web of Science ®Google Scholar
• Madersbacher S, Hochreiter W, Burkhard F et al. Radical cystectomy for bladder cancer today – a homogeneous series without neoadjuvant therapy. J. Clin. Oncol.21(4), 690–696 (2003).
   PubMed Web of Science ®Google Scholar
• Shariat SF, Karakiewicz PI, Palapattu GS et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J. Urol.176(6), 2414–2422 (2006).
   PubMed Web of Science ®Google Scholar
• von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol.23(21), 4602–4608 (2005).
   PubMed Web of Science ®Google Scholar
• Sternberg CN. Neo-adjuvant and adjuvant chemotherapy of bladder cancer: is there a role? Ann. Oncol.13(Suppl. 4), 273–279 (2002).
   PubMedGoogle Scholar
• Millikan R, Dinney C, Swanson D et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J. Clin. Oncol.19(20), 4005–4013 (2001).
   PubMed Web of Science ®Google Scholar
• Herr HW, Scher HI. Surgery of invasive bladder cancer: is pathologic staging necessary? Semin. Oncol.17(5), 590–597 (1990).
   Google Scholar
• Sternberg CN, Pansadoro V, Calabro F et al. Can patient selection for bladder preservation be based on response to chemotherapy? Cancer97(7), 1644–1652 (2003).
   PubMedGoogle Scholar
• Wallace DM, Raghavan D, Kelly KA et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br. J. Urol.67(6), 608–615 (1991).
   PubMedGoogle Scholar
• Martinez-Pineiro JA, Gonzalez Martin M, Arocena F et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized Phase III study. J. Urol.153(3 Pt 2), 964–973 (1995).
   PubMed Web of Science ®Google Scholar
• Rintala E, Hannisdahl E, Fossa SD et al. Neoadjuvant chemotherapy in bladder cancer: a randomized study. Nordic Cystectomy Trial I. Scand. J. Urol. Nephrol.27(3), 355–362 (1993).
   PubMed Web of Science ®Google Scholar
• Malmstrom PU, Rintala E, Wahlqvist R et al. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J. Urol.155(6), 1903–1906 (1996).
   PubMed Web of Science ®Google Scholar
• Sherif A, Rintala E, Mestad O et al. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer – Nordic cystectomy trial 2. Scand. J. Urol. Nephrol.36(6), 419–425 (2002).
   PubMed Web of Science ®Google Scholar
• Logothetis C, Swanson D, Amato R et al. Optimal delivery of perioperative chemotherapy: preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma. J. Urol.155(4), 1241–1245 (1996).
   Google Scholar
• No authors listed. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet354(9178), 533–540 (1999).
   PubMed Web of Science ®Google Scholar
• Hall RR. Updated results of a randomized controlled trial of neoadjuvant cisplatin (C), methotrexate (M) and vinblastine (V) chemotherapy for muscle invasive bladder cancer. Proc. Am. Soc. Clin. Oncol.21 (2002) (Abstract 710).
   Google Scholar
• Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med.349(9), 859–866 (2003).
   PubMed Web of Science ®Google Scholar
• No authors listed. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet361(9373), 1927–1934 (2003).
   PubMed Web of Science ®Google Scholar
• Vale CL. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data: advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol.48(2), 202–206 (2005).
   PubMed Web of Science ®Google Scholar
• Winquist E, Kirchner TS, Segal R et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J. Urol.171(2 Pt 1), 561–569 (2004).
   PubMed Web of Science ®Google Scholar
• Kassouf W, Philippe ES, Gordon AB et al. P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur. Urol.52(3), 769–776 (2007).
   Google Scholar
• Dash A, Pettus JAI, Bochner BH et al. Efficacy of neo-adjuvant gemcitabine plus cisplatin (GC) in muscle-invasive urothelial cancer (UC). J. Clin. Oncol.25(18 Suppl.), 5077 (2007).
   Google Scholar
• Miladi M, Peyromaure M, Zerbib M et al. The value of a second transurethral resection in evaluating patients with bladder tumours. Eur. Urol.43(3), 241–245 (2003).
   PubMed Web of Science ®Google Scholar
• Studer UE, Bacchi M, Biedermann C et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J. Urol.152(1), 81–84 (1994).
   PubMed Web of Science ®Google Scholar
• Skinner DG, Daniels JR, Russell CA et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J. Urol.145(3), 459–464; discussion 464–467 (1991).
   PubMed Web of Science ®Google Scholar
• Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J. Urol.155(2), 495–499; discussion 499–500 (1996).
   PubMed Web of Science ®Google Scholar
• Stockle M, Meyenburg W, Wellek S et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J. Urol.148(2 Pt 1), 302–306; discussion 306–307 (1992).
   PubMed Web of Science ®Google Scholar
• Stockle M, Wellek S, Meyenburg W et al. Radical cystectomy with or without adjuvant polychemotherapy for non-organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymph node involvement. Urology48(6), 868–875 (1996).
   PubMed Web of Science ®Google Scholar
• No authors listed. Adjuvant chemotherapy for invasive bladder cancer (individual patient data). Cochrane Database Syst. Rev. (2), CD006018 (2006).
   Google Scholar
• Dogliotti L, Carteni G, Siena S et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized Phase II trial. Eur. Urol.52(1), 134–141 (2006).
   Google Scholar
• Bellmunt J, Ribas A, Eres N et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer80(10), 1966–1972 (1997).
   PubMed Web of Science ®Google Scholar
• Dreicer R, Manola J, Roth BJ et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer100(8), 1639–1645 (2004).
   PubMed Web of Science ®Google Scholar
• David KA, Milowsky MI, Ritchey J et al. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J. Urol.178(2), 451–454 (2007).
   PubMed Web of Science ®Google Scholar
• Tuazon ED, Groshen SG, Lerner SP et al. Patient randomization factors in the P53 targeted therapy trial in bladder cancer (SWOG 4B951). J. Urol.177(4), 192 (2007) (Abstract 576).
   Google Scholar
• Bono A, Benvenuti C, Gibba A. Adjuvant chemotherapy in locally advanced bladder cancer. Final analysis of a controlled multicentre study. Acta Urol. Ital.11, 5–8 (1997).
   Google Scholar
• Shipley WU, Winter KA, Kaufman DS et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J. Clin. Oncol.16(11), 3576–3583 (1998).
   Google Scholar
• Sengelov L, von der Maase H, Lundbeck F et al. Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours. Acta Oncol.41(5), 447–456 (2002).
   Google Scholar